I am a physician scientist who has championed research that has driven improvements in clinical practicein immunology, infectious diseases, drug hypersensitivity and HIV. My most important contributions have included 1. The first studies on the recognition and management of immune restoration disease in HIV, 2. The early use of HIV cohort studies for both research and clinical practice with development of novel statisticalmethods, 3. The recognition and characterization of thymidine-analogue associated lipoatrophy and othermitochondrial toxicities, 4. The discovery and translation of pharmacogenetic testing to prevent abacavir and other drug hypersensitivity syndromes and characterization of the pathogenesis of these syndromes, and 5. The innovation of population based host-pathogen genetic analyses to characterize pathogen adaptation to host alleles to facilitate pathogenesis studies, epitope discovery and immunogen design. Our group discovered the association between HLA-B*5701 and abacavir hypersensitivity and championed its successfultranslation to the T4 stage of routine pharmacogenetic testing in primary care with collaborators internationally.I continue to research drug hypersensitivity, the adaptation of HIV and other pathogens to HLA restrictedimmune responses and the role of inflated memory T-cell responses to CMV and other T cells in cardiovascular and other diseases by focusing on HLA-allele/epitope/T-cell receptor specific interactions from a population to single-cell level. I have mentored more than 30, now independent scientists and established the Institute forImmunology and Infectious Diseases in Australia, and the Center for Translational Immunology and Infectious Diseases at Vanderbilt University which are intra-operable and have particular strength in quality assurance,automation, bulk and single cell cellular and genetic technology, bio-informatics and statistics. I am also the Scientific Director of the VANTAGE Core that offers extensive suite of genetic assays including high-throughput genotyping, next-generation sequencing and bio-banking and support sophisticated downstream dataanalysis. My current focus is to apply our microbial and immunogenomics and single-cell pipeline for thegeneration, analysis and visualization of cost-effective, high dimensional single cell data to critical clinicaland scientific questions that improve outcomes for patients living with HIV. I serve as Director of the TN-CFAR.